We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Albireo

News List

Albireo’s Bylvay approved in EU and US for rare paediatric liver disease pharmatimes
July 23, 2021
Albireo Pharma’s Bylvay has received approval on both sides of the Atlantic this week, scoring authorisation in the EU and US for the treatment of all subtypes of progressive familial intrahepatic cholestasis (PFIC).
Albireo wins back-to-back US, EU nods for bile acid modulator Bylvay firstwordpharma
July 21, 2021
Albireo Pharma on Tuesday said the FDA cleared Bylvay (odevixibat) to treat moderate-to-severe itching in patients aged three months and older with progressive familial intrahepatic cholestasis (PFIC), making it the first drug approved for all subtypes of
Albireo submits rare liver disease med odevixibat to FDA and EMA pharmatimes
December 14, 2020
Albireo Pharma has submitted odevixibat to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), seeking approval for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH drugs
April 18, 2019
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH